These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 18385183

  • 21. Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study.
    Nojszewska M, Potulska-Chromik A, Jamrozik Z, Janik P, Zakrzewska-Pniewska B.
    Neurol Neurochir Pol; 2019; 53(1):26-33. PubMed ID: 30620042
    [Abstract] [Full Text] [Related]

  • 22. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T.
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [Abstract] [Full Text] [Related]

  • 23. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
    Liscic RM, Srulijes K, Gröger A, Maetzler W, Berg D.
    Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
    [Abstract] [Full Text] [Related]

  • 24. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC, Thornton JS, Lees AJ, Jäger HR.
    Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
    [Abstract] [Full Text] [Related]

  • 25. In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism.
    Srulijes K, Mallien G, Bauer S, Dietzel E, Gröger A, Ebersbach G, Berg D, Maetzler W.
    J Neural Transm (Vienna); 2011 Aug; 118(8):1191-7. PubMed ID: 21207078
    [Abstract] [Full Text] [Related]

  • 26. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.
    Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, Dichgans J, Klockgether T.
    Ann Neurol; 1999 Jan; 45(1):65-74. PubMed ID: 9894879
    [Abstract] [Full Text] [Related]

  • 27. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, D'Olhaberriague L, Chaudhuri KR, Pearce RK.
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990.
    Bower JH, Maraganore DM, McDonnell SK, Rocca WA.
    Neurology; 1997 Nov; 49(5):1284-8. PubMed ID: 9371909
    [Abstract] [Full Text] [Related]

  • 30. Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges.
    Respondek G, Levin J, Höglinger GU.
    Curr Opin Neurol; 2018 Aug; 31(4):448-454. PubMed ID: 29746401
    [Abstract] [Full Text] [Related]

  • 31. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T, Kametaka S, Ohta Y, Morimoto N, Deguchi S, Deguchi K, Ikeda Y, Takao Y, Ohta T, Manabe Y, Sato S, Abe K.
    Intern Med; 2011 Aug; 50(22):2775-81. PubMed ID: 22082889
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical correlates of fear of falling in progressive supranuclear palsy and multiple system atrophy.
    Martínez-Villota VA, Terroba-Chambi C, Castillo-Torres SA, Rossi M, Merello M.
    Eur J Neurol; 2023 Aug; 30(8):2261-2266. PubMed ID: 37183570
    [Abstract] [Full Text] [Related]

  • 34. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.
    Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, Lanza P, Barone P, Morgante L, Zappia M, Aguglia U, Gallo O.
    Radiology; 2008 Jan; 246(1):214-21. PubMed ID: 17991785
    [Abstract] [Full Text] [Related]

  • 35. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
    Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW.
    Neurology; 2015 Aug 04; 85(5):404-12. PubMed ID: 26138942
    [Abstract] [Full Text] [Related]

  • 36. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA.
    Neurodegener Dis; 2008 Aug 04; 5(6):339-46. PubMed ID: 18349518
    [Abstract] [Full Text] [Related]

  • 37. Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders.
    Yamamoto T, Tateno F, Sakakibara R, Furukawa S, Asahina M, Uchiyama T, Hirano S, Yamanaka Y, Fuse M, Koga Y, Yanagisawa M, Kuwabara S.
    PLoS One; 2016 Aug 04; 11(2):e0149278. PubMed ID: 26886104
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center.
    Xie T, Kang UJ, Kuo SH, Poulopoulos M, Greene P, Fahn S.
    NPJ Parkinsons Dis; 2015 Aug 04; 1():15007. PubMed ID: 28725681
    [Abstract] [Full Text] [Related]

  • 40. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
    Yoshita M, Hayashi M, Hirai S.
    Rinsho Shinkeigaku; 1997 Jun 04; 37(6):476-82. PubMed ID: 9366173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.